<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47583">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486757</url>
  </required_header>
  <id_info>
    <org_study_id>2013P-000513</org_study_id>
    <nct_id>NCT02486757</nct_id>
  </id_info>
  <brief_title>Investigation of Female Reproductive Hormone Dynamics During Adolescence</brief_title>
  <official_title>Investigation of Female Reproductive Hormone Dynamics During Adolescence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irregular menstrual cycles are common in girls for several years after their first menstrual
      period. The cause of abnormal menstrual cycles during this time is not well-understood. The
      purpose of this study is to: 1) monitor girls during a menstrual cycle (with blood and urine
      sampling and serial pelvic ultrasounds) to identify those girls who do not ovulate (release
      of an egg from the ovary), and 2) determine whether cycles can be corrected by treating
      girls with a short course of low-dose estrogen and progesterone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ovulation in cycle 2</measure>
    <time_frame>20-40 days</time_frame>
    <description>serum progesterone &gt; 3 ng/ml or presence of corpus luteum on pelvic ultrasound</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Menstruation Disturbances</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>blood and urine sampling and serial pelvic ultrasounds during cycle 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micronized progesterone</intervention_name>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>transdermal estradiol</intervention_name>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no more than 3 Â½ years postmenarchal

        Exclusion Criteria:

          -  Subjects currently on or previously treated with medications that may affect
             reproductive hormones (eg birth control pills).

          -  Subjects with severe acne or hirsutism

          -  Subjects who exercise excessively (running &gt; 20 miles/week or its equivalent)

          -  Subjects with any of the following medical conditions: diabetes, hypertension,
             hyperlipidemia, valvular heart disease, lupus, rheumatoid arthritis, migraine
             headaches with aura, undiagnosed breast mass, inflammatory bowel disease, gallbladder
             disease, sickle cell disease, or thrombophilia.

          -  Current smoker

          -  History of deep venous thrombosis or pulmonary embolism in subject or first-degree
             relative
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natalie D Shaw, MD</last_name>
    <email>nshaw@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tairmae Kangarloo, BS</last_name>
    <phone>617-726-8622</phone>
    <email>tkangarloo@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reproductive Endocrine Unit, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Janet Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 30, 2015</lastchanged_date>
  <firstreceived_date>June 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet E. Hall, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Menstruation Disturbances</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
